Predicting risk of malignancy in adnexal masses
- PMID: 20308826
- DOI: 10.1097/AOG.0b013e3181d44053
Predicting risk of malignancy in adnexal masses
Abstract
Objective: To estimate the accuracy of preoperative ultrasonography, serum CA 125, and patient demographics as a means of predicting risk of malignancy in women with a ultrasonographically confirmed adnexal mass.
Methods: Tumor morphology derived from ultrasonographic images, tumor size, tumor bilaterality, serum CA 125, and patient demographics were evaluated preoperatively in 395 patients undergoing surgery from 2001 to 2008. Tumor morphology was classified as complex, solid, or cystic. Preoperative findings were compared with tumor histologic findings at the time of surgery. Multivariable classification and regression tree analysis were used to identify a group of patients at high risk of ovarian malignancy.
Results: One hundred eighteen patients had ovarian cancer, 13 patients had ovarian tumors of borderline malignancy, and 264 had benign ovarian tumors. Multivariable classification and regression tree analysis defined women at high risk of ovarian malignancy as those with an adnexal mass having complex or solid morphology and a serum CA 125 value greater than 35 units/mL. This definition had a positive predictive value of 84.7% and a negative predictive value of 92.4% and correctly identified 77.3% of patients with stage I and stage II ovarian cancer and 98.6% of patients with stage III and stage IV ovarian cancer.
Conclusion: Patients with solid or complex ovarian tumors and an elevated serum CA 125 level (greater than 35 units/mL) are at high risk of ovarian malignancy.
Level of evidence: II.
Comment in
-
Adnexal masses: when to observe, when to intervene, and when to refer.Obstet Gynecol. 2010 Apr;115(4):680-681. doi: 10.1097/AOG.0b013e3181d686ed. Obstet Gynecol. 2010. PMID: 20308824 No abstract available.
Similar articles
-
Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.J Natl Cancer Inst. 2007 Nov 21;99(22):1706-14. doi: 10.1093/jnci/djm199. Epub 2007 Nov 13. J Natl Cancer Inst. 2007. PMID: 18000221
-
Evaluation of adnexal masses with three-dimensional ultrasonography.Obstet Gynecol. 2006 Nov;108(5):1167-75. doi: 10.1097/01.AOG.0000240138.24546.37. Obstet Gynecol. 2006. PMID: 17077239
-
Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.Ultrasound Obstet Gynecol. 2019 Dec;54(6):815-822. doi: 10.1002/uog.20363. Epub 2019 Nov 11. Ultrasound Obstet Gynecol. 2019. PMID: 31152572
-
CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.Int J Biol Markers. 2015 Jul 22;30(3):e333-40. doi: 10.5301/jbm.5000139. Int J Biol Markers. 2015. PMID: 25704505 Review.
-
Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer.Clin Exp Obstet Gynecol. 2004;31(2):85-98. Clin Exp Obstet Gynecol. 2004. PMID: 15266758 Review.
Cited by
-
Immunohistochemical Evaluation of Notch1 in Ovarian Tumours and Its Prognostic Implications.Cureus. 2023 Jun 22;15(6):e40830. doi: 10.7759/cureus.40830. eCollection 2023 Jun. Cureus. 2023. PMID: 37489207 Free PMC article.
-
Assessment of Diagnostic Value of Serum Ca-125 and Risk of Malignancy Index Scoring in the Evaluation of Adnexal Masses.J Midlife Health. 2019 Oct-Dec;10(4):192-196. doi: 10.4103/jmh.JMH_84_19. J Midlife Health. 2019. PMID: 31942155 Free PMC article.
-
The role of preoperative imaging and tumor markers in predicting malignant ovarian masses in children.Pediatr Surg Int. 2020 Mar;36(3):333-339. doi: 10.1007/s00383-019-04591-1. Epub 2019 Nov 7. Pediatr Surg Int. 2020. PMID: 31701303
-
Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.Medicine (Baltimore). 2019 Feb;98(7):e14577. doi: 10.1097/MD.0000000000014577. Medicine (Baltimore). 2019. PMID: 30762809 Free PMC article.
-
Mucinous borderline ovarian tumor: a case report with diagnostic insights on ultrasound findings.J Ultrason. 2016 Dec;16(67):411-416. doi: 10.15557/JoU.2016.0041. Epub 2016 Dec 30. J Ultrason. 2016. PMID: 28138412 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics 2009. CA Cancer J Clin 2009;59:225–49.
-
- Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705–12.
-
- Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 2005;104:1398–407.
-
- Goff BA, Mandel L, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index. Cancer 2007;109:221–7.
-
- Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–59.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
